VolitionRx’s (VNRX) Buy Rating Reiterated at D. Boral Capital

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $5.00 price objective on the stock.

VNRX has been the topic of a number of other research reports. StockNews.com assumed coverage on shares of VolitionRx in a research report on Friday. They set a “sell” rating on the stock. Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Stock Performance

Shares of VNRX opened at $0.62 on Tuesday. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.23. The firm has a market cap of $57.22 million, a price-to-earnings ratio of -1.72 and a beta of 1.17. The business’s fifty day moving average is $0.69 and its 200-day moving average is $0.67.

Institutional Trading of VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC grew its position in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.